Core Insights - West Pharmaceutical Services, Inc. reported solid growth in both Proprietary Products and Contract Manufacturing segments, achieving double-digit growth in HVP Components, driven by strong demand for GLP-1 products and improved HVP conversion [2][3][8] - The company has increased its full-year 2025 revenue and EPS guidance due to strong performance and ongoing business momentum [2][9] Financial Performance - For the third quarter of 2025, net sales reached $804.6 million, a 7.7% increase compared to the same period last year, with organic growth of 5.0% [7][24] - Proprietary Products segment net sales were $647.5 million, growing by 7.7% and 5.1% on an organic basis [2][7] - Contract-Manufactured Products segment net sales increased by 8.0% to $157.1 million, with organic growth of 4.9% [3][24] Segment Analysis - High-Value Product (HVP) Components net sales were $390.0 million, reflecting a 16.3% increase and 13.3% organic growth, accounting for 48% of total company net sales [8][24] - HVP Delivery Devices saw a decline in net sales to $99.1 million, down 15.7% due to a prior one-time incentive fee [8][24] - Standard Products segment net sales increased by 6.7% to $158.4 million, with organic growth of 3.6% [8][24] Cash Flow and Share Repurchase - Operating cash flow for the first nine months of 2025 was $503.7 million, an increase of 8.7% year-over-year, while free cash flow rose by 53.7% to $293.9 million [4][5] - The company repurchased 552,593 shares for $134.0 million at an average price of $242.55 [5] Updated Guidance - Full-year 2025 net sales guidance has been raised to a range of $3.060 billion to $3.070 billion, up from the previous range of $3.040 billion to $3.060 billion [9][10] - Adjusted-diluted EPS guidance for 2025 has also been increased to a range of $7.06 to $7.11, compared to the prior range of $6.65 to $6.85 [9][10]

West Pharmaceutical Services, Inc. Eric M. Green President, CEO and Chair of the Board William Blair 45th Annual Growth Stock Conference June 5, 2025 Safe Harbor Statement Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about product develop ...